Background: Concurrent chemoradiotherapy is standard of care for the management of cervical cancer. Objective: In this study we try to explore various prognostic factors for management of cervical cancer, stage II. The main objective was to analyze impact of various factors on disease response and toxicities. Methods: This is a prospective analysis of 50 patients of stage II cervical cancer, treated with concurrent chemoradiotherapy. The most common regime used was Concurrent EBRT (External Beam Radiotherapy) + HDR (High Dose Rate) ICBT (Intra cavitary Brachytherapy) + weekly cisplatin (40 mg/m 2 ). The most common dose fractionation regime was 7.5 Gy X 3 fractions or 6 Gy X 4 fractions. A total dose of 50 Gy was delivered by EBRT. Results: Of the 50 patients, 14 patients (28%) were in stage IIa while 36 (72%) were in stage IIb. 41 (82%) achieved CR. Conclusion: Out of the various factors analyzed NLR (Neutrophil-Leucocyte Ratio), pre-treatment Hb (Hemoglobin) value, number of weekly cisplatin cycle received were the only factors with significant impact on prognosis.
Introduction
Carcinoma of the uterine cervix (cervical cancer) is the second most common malignancy seen in Indian females (1) . In India 60000 death occur every year is caused by carcinoma cervix (2) . It is third leading cause of female cancer and 4 th www.jmscr.igmpublication.org Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i2.60 leading cancer cause of female deaths in India (3) . Worldwide, it is overall tenth common malignancy (4) . Around 0.5 million new cases of carcinoma cervix are diagnosed annually in world. It is more common in rural (about 65 percent) than urban (about 35 percent). Patients of cervical cancer in India usually present in FIGO (International Federation of Gynecology & Obstetrics)) stage II (35%), or in stage III (43%) with 88% of total cases having squamous histology (5) . This allows to use surgery and RT (Radiotherapy) as the primary modality of treatment. Surgery has a role mainly in localized tumor of 4 cm or less size. RT is recommended in patients with primary tumor of >4 cm size or patient who either refuse or are not fit for surgery. Treatment of choice for most patients with early stage (IB&IIA) disease is either radiation therapy or surgery. NCCN have category one recommendations for surgery or radiotherapy in stage IB1 & IIA1 while concurrent chemoradiotherapy as category one for stage IB2 & IIA2 and onward (6) . Radiotherapy is a combination of external beam irradiation and brachytherapy is used. External beam radiation is used to treat the central disease and to sterilize known or suspected regional metastases. Early stage non-bulky disease is suitable for simultaneous application brachytherapy and EBRT. Any treatment of advanced cervical cancer (Ib -IVa) with RT is incomplete without the use of BT (Brachytherapy). ABS recommend use of BT whenever possible for completion of successful treatment of cervical cancer with radiotherapy (Nag S el al.) (7) . Total treatment duration (EBRT& ICBT) must be less than 8 weeks (8) . Several studies have suggested that there may be as much as 1% decrease in survival and local control for each extra day of treatment beyond a total treatment time of 55 to 60 day (9) . ABS also recommend maintaining fraction size to < 7.5 Gy for each application of BT (10) with 4 to 8 fractions, because higher dose per fraction are associated with higher toxicities. To achieve this, we used concurrent HDR ICBT with EBRT regimes only for the management of patients. The addition of concurrent cisplatin-based chemotherapy to radiotherapy reduced the risk of death by 30 percent to 50 percent.U.S. National Cancer Institute Bulletin about use of chemoradiotherapy has also advocated addition of chemotherapy with EBRT (11) . In this study we used weekly cisplatin with a dose of 40 mg/m 2 on every Sunday. This study compares the effects of various factors on disease response and toxicities in cervical cancer patients treated with concurrent HDR ICBT with EBRT and weekly cisplatin (40 mg/m 2 ).
Materials and Methods
This is a prospective randomized control study carried in department of Radiotherapy at Acharya Tulsi Regional cancer treatment center Bikaner. 50 patients with biopsy proven cases of carcinoma cervix were included and received concurrent CT (inj. Cisplatin 40 mg/m 2 wkly) + EBRT upto 50Gy to whole pelvis + HDR ICBT. The ICBT was started only when patient had received 20 Gy (10 fractions) of EBRT on wkly schedule on every Saturday. Weekly chemotherapy was given on every Sunday. Application of ICBT was performed on an outpatient basis with non-narcotic analgesics. For ICBT simulation, orthogonal films of anteroposterior and lateral views were taken with the applicators inserted, and the position of point A, bladder and rectal points were defined according to the Manchester method and ICRU (International Commission on Radiation Units and Measurement) 38 recommendations. The Linear Quadratic equation was used to calculate the dose to point A and the BED for Arm A was 98.4 Gy and for Arm B it was 98.8 Gy. All patients were able to complete planned treatment in both Arms. The median time of follow-up was 14 months for whole study (range 7 -20 months). Mean duration for treatment completion was 42.82 days (43.12 days for Arm A and 42.52 days for Arm B).
Follow up
All patients were followed up at 3 and 6 months after treatment completion for disease response and toxicities. Toxicities were analysed by using RTOG (Radiation Therapy Oncology Group)/ EORTC (European Organisation for Research and Treatment of Cancer) criteria (13) .
Statistical Analysis
The primary outcome measure was DFS (Disease Free Survival), which was defined as the time from the starting date of initial treatment to any progression of disease. Data were tabulated in MS Excel 2016 and analysis IBM SPSS Statistics 25 software was used for statistical analysis. For statistical significance of the difference in proportions Chi-square test was used. Kaplan-Meier method was used to analyze local control, disease-free survival, overall survival, and late complication rates, and the differences between the two arms were analyzed by log-rank test. for significance of results, p value should be <0.05. To assess the effect of number of weekly cisplatin (40 mg/m2) cycles on response rate, patients were divided into two groups. Those patients who due to complications received less than 5 weekly cisplatin cycles were included in group 1, while those patients who were able to receive all 5 weekly cisplatin cycles included in group 2. A total of 22 patients were in group 1, while 28 were in group 2. Out of 22 patients only 14 were able to achieve CR in group 1. In group 2, 27 patients out of 28 were able to attain CR (p value = .05).
Results
To assess the effect of pre-treatment NLR (Neutrophil to lymphocyte ratio), patients were divided into two groups; Group 1 contain patients with NLR value < 2.95 while group 2 with NLR value of > 2.95. Out of 50 patients 30 patients (60%) were in group 1 while remaining 20 (40%) were in group 2. In group 1, 28 patients were able to attain CR, while in group 2 CR was attained by 13 patients (p value = .036).
Conclusion
For patients of stage II cervical cancer treated with concurrent chemoradiotherapy with short overall treatment time (<8 weeks), pre-treatment Hb, number of weekly cisplatin cycles received and pre-treatment NLR were the most important prognostic factors associated with disease response.
